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The potential danger of journal 
summary services
To the Editor: On 29 April, NEJM Journal Watch published a sum-
mary[1] of a recent trial of single-dose dexamethasone for acute 
asthma compared with the current standard of 5-day prednisone. 
Unfortunately the one-line opening paragraph of the summary 
(which was the only line in the email alert) stated the opposite of the 
actual outcome of the trial.
The one-line summary stated: ‘A randomized trial suggests that 
the regimens may be equivalent.’ The study[2] was designed as a non-
inferiority trial and dexamethasone in fact failed (albeit narrowly) to 
meet the prespecified parameters of non-inferiority. 
In the current environment where medical practitioners are 
bombarded by data, it is likely that many would read the one-
line summary without reading the full summary, let alone the 
original article. It is even conceivable that practitioners around 
the world might change their practice on the basis of this one-
line summary, especially with the summary promoted as ‘practice 
changing’ on the website. NEJM Journal Watch’s reported global 
monthly readership is half a million;[3] the concomitant pressures 
of drug company direct marketing are significant; and the fact 
that studies have shown equivalence between 5 days of predni-
sone and two doses of dexamethasone could easily be confused 
with this result.
There are potentially grave consequences from such a practice 
change: the raw data from the study yield an NNH (number needed 
to harm) of 43 for using single-dose dexamethasone instead of 5-day 
prednisone. This is a worrying statistic for a condition that is both 
common and potentially lethal, especially when one notices that the 
study’s loss to follow-up (an attempted phone call at 2 weeks) was 
nearly twice as high in the dexamethasone group as in the prednisone 
group. 
Adherence is clearly the appeal of a single-dose regimen, but it 
should be pointed out that, besides the factor of script fulfillment, 
prednisone adherence was in fact intrinsically controlled for in the 
study. And, in my particular context and through most of the rest 
of Africa where discharge medicines are provided free by the state 
and are often dispensed directly from emergency departments, script 
fulfillment is a minor aspect of adherence challenges.
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